日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease

克罗恩病患者继发性疗效丧失后，使用乌司奴单抗静脉注射进行再诱导治疗

期刊:Inflammatory Bowel Diseases
影响因子:4.3
doi:10.1093/ibd/izaf163
Schreiber, Stefan; Lee, Scott D; van der Woude, C Janneke; Marín-Jiménez, Ignacio; Wolf, Douglas C; Schnoy, Elisabeth; Salzberg, Bruce; Busse, Christopher; Nazar, Maciej; Ma, Tony; Borghorst, Stephan; Gasink, Christopher; Baker, Thomas; Godwin, Bridget; Adedokun, Omoniyi J; Feagan, Brian G
克罗恩病
发表日期：2025
文献求助 收藏

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis

乌司奴单抗治疗炎症性肠病的安全性：克罗恩病患者5年和溃疡性结肠炎患者4年的汇总安全性分析

期刊:Journal of Crohns & Colitis
影响因子:8.7
doi:10.1093/ecco-jcc/jjae013
Ghosh, Subrata; Feagan, Brian G; Ott, Elyssa; Gasink, Christopher; Godwin, Bridget; Marano, Colleen; Miao, Ye; Ma, Tony; Loftus, Edward V Jr; Sandborn, William J; Danese, Silvio; Abreu, Maria T; Sands, Bruce E
炎症
肠炎
炎症/感染
克罗恩病
结肠炎
发表日期：2024
文献求助 收藏

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection

CERTAIN-1 是一项针对复杂性尿路感染成人患者的 3 期研究，比较了头孢吡肟-他尼博巴坦与美罗培南的疗效。研究分析了基线病原体耐药表型和基因型与患者结局之间的关系。

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00236-24
Moeck, Greg; Gasink, Leanne B; Mendes, Rodrigo E; Woosley, Leah N; Dorr, MaryBeth; Chen, Hongzi; Wagenlehner, Florian M; Henkel, Tim; McGovern, Paul C
炎症/感染
微生物学
发表日期：2024
文献求助 收藏

HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients

HLA-DQA1*05 与溃疡性结肠炎和克罗恩病患者乌司奴单抗治疗反应丧失和抗药抗体无关

期刊:Inflammatory Bowel Diseases
影响因子:4.3
doi:10.1093/ibd/izad273
Colombel, Jean-Frédéric; Martín-Arranz, María D; Brinkman, Brigitta; Guan, Meijian; Hart, Amy; Gasink, Christopher
结肠炎
克罗恩病
肠炎
发表日期：2024
文献求助 收藏

Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects

抗酸剂（氢氧化铝/氢氧化镁/西甲硅油）或质子泵抑制剂（奥美拉唑）对健康成年受试者替比培南匹酯氢溴酸盐（TBP-PI-HBr）药代动力学的影响

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.01495-22
Patel, Gina; Gupta, Vipul K; Gasink, Leanne; Bajraktari, Floni; Lei, Yang; Jain, Akash; Srivastava, Praveen; Talley, Angela K
TBP
发表日期：2023
文献求助 收藏

Absorption, Metabolism, and Excretion of [(14)C]-Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Male Subjects

健康男性受试者对[(14)C]-替比培南匹酯氢溴酸盐(TBP-PI-HBr)的吸收、代谢和排泄

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.01509-22
Gupta, Vipul K; Maier, Gary; Gasink, Leanne; Ek, Amanda; Fudeman, Mary; Srivastava, Praveen; Talley, Angela
TBP
代谢
发表日期：2023
文献求助 收藏

Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial

乌司奴单抗治疗克罗恩病五年疗效和安全性：IM-UNITI试验

期刊:Clinical Gastroenterology and Hepatology
影响因子:12
doi:10.1016/j.cgh.2021.02.025
Sandborn, William J; Rebuck, Rory; Wang, Yuhua; Zou, Bin; Adedokun, Omoniyi J; Gasink, Christopher; Sands, Bruce E; Hanauer, Stephen B; Targan, Stephan; Ghosh, Subrata; de Villiers, Willem J S; Colombel, Jean-Frederic; Feagan, Brian G; Lynch, John P
克罗恩病
发表日期：2022
文献求助 收藏

Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment

不同程度肾功能损害患者口服替比培南匹酯氢溴酸盐的药代动力学

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.02407-21
Patel, Gina; Rodvold, Keith A; Gupta, Vipul K; Bruss, Jon; Gasink, Leanne; Bajraktari, Floni; Lei, Yang; Jain, Akash; Srivastava, Praveen; Talley, Angela K
发表日期：2022
文献求助 收藏

Bioequivalence of two oral formulations of tebipenem pivoxil hydrobromide in healthy subjects

在健康受试者中，两种口服替比培南匹酯氢溴酸盐制剂的生物等效性

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13280
Gupta, Vipul K; Patel, Gina; Gasink, Leanne; Bajraktari, Floni; Lei, Yang; Jain, Akash; Srivastava, Praveen; Talley, Angela K
发表日期：2022
文献求助 收藏

Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis

乌司奴单抗在炎症性肠病临床试验中对妊娠女性的影响：克罗恩病患者妊娠结局长达5年，溃疡性结肠炎患者妊娠结局长达2年

期刊:Crohns Colitis 360
影响因子:2.6
doi:10.1093/crocol/otac025
Abraham, Bincy P; Ott, Elyssa; Busse, Christopher; Murphy, Conor; Miller, Lindsay; Baumgart, Daniel C; Scherl, Ellen; Gasink, Christopher
炎症
肠炎
炎症/感染
克罗恩病
结肠炎
发表日期：2022
文献求助 收藏